F8 and hemophilia A: Hemophilia A mice were treated with: IL-2/IL-2mAb complexes+rapamycin+anti-CD20+FVIII (n = 4, group 1; Figure 3A); IL-2/IL-2mAb complexes+anti-CD20+FVIII (n = 4, group 2; Figure 3B); IL-2/IL-2mAb complexes+rapamycin+FVIII (n = 3, group 3; Figure 3C); anti-CD20+FVIII (n = 4, group 4; Figure 3D); and mock agents (control inhibitor mice; n = 2, group 5; Figure 3E) weekly for 4 weeks.